Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D03CNS
|
|||
Former ID |
DAP000604
|
|||
Drug Name |
Cyclothiazide
|
|||
Synonyms |
Anhydron; Aquirel; Ciclotiazida; Ciclotiazide; Cyclothiazidum; Doburil; Fluidil; Renazide; Valmiran; Ciclotiazide [DCIT]; C 9847; MDi 193; Anhydron (TN); Ciclotiazida [INN-Spanish]; Cyclothiazidum [INN-Latin]; Lilly 35,483; Cyclothiazide [USAN:INN:BAN]; Cyclothiazide (JAN/USAN/INN); 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-chloro-3-(5-norbornen-2-yl)-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-6-chloro-3-(5-norbornen-2-yl)-,1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-bicyclo(2.2.1)hept-5-en-2-yl-6-chloro-3,4-dihydro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-3,4-dihydro-, 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-(5-norbornen-2-yl)-, 1,1-dioxide; 3-(bicyclo[2.2.1]hept-5-en-2-yl)-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Bicyclo(2.2.1)hept-5-en-2-yl-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 3-Bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2H-1,2-4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(5-norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3,4-dihydro-3-(norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(2-norbornen-5-yl)-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 6-chloro-3,4-dihydro-3-(norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Congestive heart failure [ICD-11: BD10; ICD-10: I50.0] | Approved | [1], [2], [3] | |
Therapeutic Class |
Antihypertensive Agents
|
|||
Structure |
Download2D MOL |
|||
Formula |
C14H16ClN3O4S2
|
|||
Canonical SMILES |
C1C2CC(C1C=C2)C3NC4=CC(=C(C=C4S(=O)(=O)N3)S(=O)(=O)N)Cl
|
|||
InChI |
1S/C14H16ClN3O4S2/c15-10-5-11-13(6-12(10)23(16,19)20)24(21,22)18-14(17-11)9-4-7-1-2-8(9)3-7/h1-2,5-9,14,17-18H,3-4H2,(H2,16,19,20)
|
|||
InChIKey |
BOCUKUHCLICSIY-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 2259-96-3
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
583075, 7413729, 7848319, 8149965, 8151863, 10514282, 11336079, 11361318, 11373658, 11462290, 11491865, 17404884, 24278350, 26751850, 29222063, 46508269, 47291198, 47589058, 47736553, 47810814, 48110509, 48415831, 49890386, 50104549, 50104550, 50328346, 53777427, 56424127, 57321515, 85085062, 85230990, 85787796, 90341445, 92303854, 92307849, 96079565, 99301992, 103124246, 103249003, 104075181, 104171141, 104301976, 117629245, 121361127, 124749619, 124801467, 124879795, 124886816, 127543751, 134221777
|
|||
ChEBI ID |
CHEBI:31448
|
|||
SuperDrug ATC ID |
C03AA09
|
|||
SuperDrug CAS ID |
cas=000135079
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Carbonic anhydrase II (CA-II) | Target Info | Inhibitor | [4] |
KEGG Pathway | Nitrogen metabolism | |||
Proximal tubule bicarbonate reclamation | ||||
Collecting duct acid secretion | ||||
Gastric acid secretion | ||||
Pancreatic secretion | ||||
Bile secretion | ||||
NetPath Pathway | IL4 Signaling Pathway | |||
EGFR1 Signaling Pathway | ||||
Reactome | Erythrocytes take up carbon dioxide and release oxygen | |||
Erythrocytes take up oxygen and release carbon dioxide | ||||
Reversible hydration of carbon dioxide | ||||
WikiPathways | Reversible Hydration of Carbon Dioxide | |||
Uptake of Carbon Dioxide and Release of Oxygen by Erythrocytes | ||||
Uptake of Oxygen and Release of Carbon Dioxide by Erythrocytes |
References | Top | |||
---|---|---|---|---|
REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4167). | |||
REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
REF 3 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 013157. | |||
REF 4 | Selective effect of thiazides on the human osteoblast-like cell line MG-63. Kidney Int. 1996 Nov;50(5):1476-82. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.